On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

Intellia will present additional data from the ongoing Phase 1/2 study in an oral presentation at the European Academy of ...

NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

Discover Q1 2025 earnings insights from Intellia Therapeutics (NTLA): Phase 3 progress, RMAT milestones, financial outlook, and competitive gene editing edge.

and nexiguran ziclumeran (nex-z) for ATTR amyloidosis as it anticipates its first commercial launch in 2027. The discontinued programmes are headed by NTLA-3001, an in vivo CRISPR drug developed ...

The Vivo X200 FE will be a compact offering equipped with a 6.1-inch LTPO OLED panel that will support a 1.5K resolution and a 120Hz refresh rate. Under the hood, the device is expected to feature ...

HUTCHINSON, Kan. (KCTV) - The Kansas State Fair has announced another country music legend to perform at the Nex-tech Grandstand stage. Lorrie Morgan with Mason Ramsey will perform on Sept.

The Vivo Y300 5G features a 6.67-inch (2400 ×1080 pixels) Full HD+ E4 AMOLED screen with a 120Hz refresh rate. It is powered by the Snapdragon 4 Gen 2 processor paired with 8GB RAM and up to ...

This broad approach, called in vivo cell therapy, has the potential to offer the best of both worlds, with scalability and lower cost, not to mention a better safety profile, while maintaining the ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...